Medicure (MCUJF) Non-Current Debt (2009 - 2026)

Medicure's (MCUJF) quarterly Non-Current Debt came in at $62711.7 in Q1 2026, up 4.11% quarter-over-quarter from $60235.2 in Q4 2025.

Medicure (MCUJF) Non-Current Debt (2009 - 2026) Analysis & Trends

Medicure's Non-Current Debt history runs 13 years deep, the most recent figure standing at $62711.7 for Q1 2026.

On a quarterly basis, Non-Current Debt changed N/A year-over-year to $62711.7 in Q1 2026; TTM through Mar 2026 was $62711.7, a N/A change from a year earlier, with the FY2025 full-year figure at $60120.6, changed N/A from the prior year.
Non-Current Debt advanced to $62711.7 in Q1 2026 per MCUJF's latest filing, from $60235.2 in the prior quarter.
Across five years, Non-Current Debt topped out at $62711.7 in Q1 2026 and bottomed at $59180.4 in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Haleon	87.22 Bn	85.35 Bn	-	10.34 Bn
2	Teva Pharmaceutical Industries	39.60 Bn	35.87 Bn	1.97 Bn	14.02 Bn
3	Zoetis	31.46 Bn	29.52 Bn	1.62 Bn	9.05 Bn
4	Takeda Pharmaceutical	26.49 Bn	22.44 Bn	4.39 Bn	27.86 Bn
5	United Therapeutics	23.03 Bn	20.88 Bn	648.10 Mn	-
6	Universe Pharmaceuticals	23.03 Bn	-10.56 Bn	-	-
7	Viatris	20.90 Bn	19.09 Bn	1.16 Bn	12.41 Bn
8	Neurocrine Biosciences	17.50 Bn	16.19 Bn	800.70 Mn	-
9	Elanco Animal Health	12.33 Bn	11.91 Bn	785.00 Mn	3.74 Bn
10	Medicure	8.77 Mn	7.64 Mn	2.57 Mn	62,711.69

Download Data